Lung Cancer
Volume 62, Issue 1 , Pages 15-22 , October 2008

CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer

  • Zeyi Liu

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • ,
  • Jun Zhao

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • The First Affiliated Hospital, Suzhou University, Suzhou, PR China
    • ,
  • Xiao-Feng Chen

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • Department of Surgery, Shanghai Hospital for Pulmonary Diseases, Shanghai, PR China
    • ,
  • Wenwen Li

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • ,
  • Rengyun Liu

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • ,
  • Zhe Lei

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • ,
  • Xia Liu

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • ,
  • Xiaobei Peng

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • ,
  • Ke Xu

      Affiliations

    • Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300052, PR China
    • ,
  • Jun Chen

      Affiliations

    • Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300052, PR China
    • ,
  • Hongyu Liu

      Affiliations

    • Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300052, PR China
    • ,
  • Qing-Hua Zhou

      Affiliations

    • Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300052, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 22 60363020; fax: +86 22 60363013.
    • ,
  • Hong-Tao Zhang

      Affiliations

    • Laboratory of Medical Genetics, School of Basic Medicine & Biological Sciences, Suzhou University, 199 Ren’ai Road, Sino-Singapore Industrial Park, 215123 Suzhou, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 512 65882809; fax: +86 512 65584083.

Received 22 November 2007 ,Revised 15 January 2008 ,Accepted 5 February 2008.

References 

  1. Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer. 2004;90:2157–2166
  2. Zhong S, Fields CR, Su N, Pan YX, Robertson KD. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene. 2007;26:2621–2634
  3. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–3756
  4. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–2054
  5. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632–4642
  6. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249–255
  7. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001;1:61–67
  8. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer. 2003;103:153–160
  9. Zöchbauer-Müller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist. 2002;7:451–457
  10. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006;12:7329–7338
  11. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, et al. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene. 2001;20:1765–1770
  12. Minna JD, Fong K, Zöchbauer-Müller S, Gazdar AF. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 2002;8:S41–S46
  13. Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J, et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. 2003;63:3743–3746
  14. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004;4:707–717
  15. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res. 2004;10:6119–6125
  16. Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer. 2004;91:771–774
  17. Kim YT, Park SJ, Lee SH, Kang HJ, Hahn S, Kang CH, et al. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 2005;130:1378
  18. Belinsky SA, Grimes MJ, Casas E, Stidley CA, Franklin WA, Bocklage TJ, et al. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer. 2007;96:1278–1283
  19. Katayama H, Hiraki A, Aoe K, Fujiwara K, Matsuo K, Maeda T, et al. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer. 2007;120:2191–2195
  20. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96:8681–8686
  21. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999;59:5438–5442
  22. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60:1835–1839
  23. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst. 2002;94:755–761
  24. Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ, et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res. 2006;66:10621–10629
  25. Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, Minna JD, et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer. 2006;106:2200–2207
  26. Zhang C, Li Z, Cheng Y, Jia F, Li R, Wu M, et al. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res. 2007;13:944–952
  27. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res. 2003;63:3724–3728
  28. Riquelme E, Tang M, Baez S, Diaz A, Pruyas M, Wistuba II, et al. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett. 2007;250:100–106
  29. Choi CH, Lee KM, Choi JJ, Kim TJ, Kim WY, Lee JW, et al. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett. 2007;255:26–33
  30. Mountain CF. Revisions in the International System for staging lung cancer. Chest. 1997;111:1710–1717
  31. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–9826
  32. Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res. 2004;10:1733–1742
  33. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999;59:1090–1095
  34. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Williams NN, et al. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. Cancer Res. 2003;63:3352–3355
  35. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001;61:3877–3881
  36. Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, et al. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer. 2003;106:60–65
  37. Zöchbauer-Müller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, et al. 5’ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 2001;61:3581–3585
  38. Zhang HT, Chen XF, Wang MH, Wang JC, Qi QY, Zhang RM, et al. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res. 2004;10:2359–2367
  39. Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer. 2006;106:1250–1259
  40. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol. 2006;17:vii97–vii102
  41. An Q, Liu Y, Gao Y, Huang J, Fong X, Li L, et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett. 2002;188:109–114
  42. Chan EC, Lam SY, Tsang KW, Lam B, Ho JC, Fu KH, et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res. 2002;8:3741–3746
  43. Ng CS, Zhang J, Wan S, Lee TW, Arifi AA, Mok T, et al. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol. 2002;79:101–106
  44. Liu Y, An Q, Li L, Zhang D, Huang J, Feng X, et al. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis. 2003;24:1897–1901
  45. Zhou XM, Shao SJ, Xu GD, Zhong RT, Liu DY, Tang JW, et al. Highly sensitive determination of the methylated p16 gene in cancer patients by microchip electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;816:145–151
  46. Xie GS, Hou AR, Li LY, Gao YN, Cheng SJ. Aberrant p16 promoter hypermethylation in bronchial mucosae as a biomarker for the early detection of lung cancer. Chin Med J (Engl). 2006;119:1469–1472
  47. Kim DS, Cha SI, Lee JH, Lee YM, Choi JE, Kim MJ, et al. Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. Lung Cancer. 2007;58:1–6
  48. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912–2919
  49. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res. 2004;64:3137–3143

PII: S0169-5002(08)00064-0

doi: 10.1016/j.lungcan.2008.02.005

Lung Cancer
Volume 62, Issue 1 , Pages 15-22 , October 2008

Article Tools

* Image Usage & Resolution